Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Deregulated expression of selected histone methylases and demethylases in prostate carcinoma

7 Nov 2013

Abstract excerpt

Prostate cancer (PCa), a leading cause of cancer-related morbidity and mortality, arises through the acquisition of genetic and epigenetic alterations. Deregulation of histone methyltransferases (HMTs) or demethylases (HDMs) has been associated with PCa development and progression. However, the precise influence of altered HMTs or HDMs expression and respective histone marks in PCa onset and progression remains...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related gene regulation
Share to Epigenetics and DNA Methylation
Share to Prostate Cancer Treatment and Research

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 24200674
DOI: 10.1530/erc-13-0375

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Deregulated expression of selected histone methylases and demethylases in prostate carcinomaPMID 24200674Read ↗

Integrated Analysis of Genetic Abnormalities of the Histone Lysine Methyltransferases in Prostate CancerSemantic proximity Read ↗

Bioinformatic determination of the expression and clinical value of the histone lysine demethylase family in prostate cancerSemantic proximity Read ↗

The emerging role of histone lysine demethylases in prostate cancerSemantic proximity Read ↗

SMYD3 contributes to a more aggressive phenotype of prostate cancer and targets Cyclin D2 through H4K20me3.Semantic proximity Read ↗

Multiple Highly Methylated CpG Sites as Potential Epigenetic Markers for the Diagnosis of Prostate CancerSemantic proximity Read ↗

Epigenetic Changes in Prostate Cancer: Implication for Diagnosis and TreatmentSemantic proximity Read ↗

Integrative analyses of DNA methylase expression and related immune landscape in Prostate CancerSemantic proximity Read ↗

Aberrant DNA Methylation and Prostate CancerSemantic proximity Read ↗

The SMYD3-MAP3K2 signaling axis promotes tumor aggressiveness and metastasis in prostate cancerSemantic proximity Read ↗

X- and Y-Linked Chromatin-Modifying Genes as Regulators of Sex-Specific Cancer Incidence and PrognosisSemantic proximity Read ↗

Histone methyltransferase PRMT6 plays an oncogenic role of in prostate cancerSemantic proximity Read ↗

DNA methylation alterations in prostate cancer: from diagnosis to treatmentSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.